Fulfilling an Unmet Need in Psoriasis: Do Biologicals Hold the Key to Improved Tolerability?

ISSN： 0114-5916

Source： Drug Safety, Vol.29, Iss.1, 2006-01, pp. : 49-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Corticosteroid-Sparing Strategies in Renal Transplantation: Are We Still Balancing Rejection Risk with Improved Tolerability?

By Bestard Oriol Cruzado Josep M. Grinyó Josep M.

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 403-414

Adis International

Access to resources Recommend Favorite

Risk of Melanoma with Psoralen/Ultraviolet A Therapy for Psoriasis: Do the Known Risks Now Outweigh the Benefits?

By Lindelöf B.

Drug Safety, Vol. 20, Iss. 4, 1999-04 ,pp. : 289-297

Adis International

Access to resources Recommend Favorite

Ustekinumab to usurp etanercept in psoriasis?

Inpharma, Vol. 1, Iss. 1658, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Antiplatelet Drugs - Do We Need New Options?: With a Reappraisal of Direct Thromboxane Inhibitors

By Coccheri Sergio

Drugs, Vol. 70, Iss. 7, 2010-05 ,pp. : 887-908

Adis International

Access to resources Recommend Favorite

Do We Need Drug Therapy to Manage Mild Hypertension in the Elderly?

By Fagard R.H.

Drugs & Aging, Vol. 21, Iss. 1, 2004-01 ,pp. : 1-6

Adis International

Access to resources Recommend Favorite